Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             362 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 Abstracts Index 2002
5 6 p. 599-605
7 p.
artikel
2 Author Index, Volume 5 2002
5 6 p. 606-
1 p.
artikel
3 CC1 LITERATURE REVIEW OF GUIDELINES FOR CROSS-CULTURAL ADAPTATION OF HRQL MEASURES: UPDATED RESULTS Conway, K
2002
5 6 p. 459-
1 p.
artikel
4 CC3 MEASURING POPULATION HEALTH FOR 191 COUNTRIES:WHO METHODS AND RESULTS Mathers, CD
2002
5 6 p. 460-
1 p.
artikel
5 CC2 RECOMMENDATIONS ON HRQL/UTILITY DATA IN 14 EUROPEAN PHARMACOECONOMIC GUIDELINES Szende, A
2002
5 6 p. 460-
1 p.
artikel
6 CN1 A STOCHASTIC ECONOMIC EVALUATION OF LETROZOLE VERSUS TAMOXIFEN AS A FIRST-LINE HORMONAL THERAPY FOR ADVANCED BREAST CANCER IN POSTMENOPAUSAL PATIENTS IN GERMANY Fricke, FU
2002
5 6 p. 443-
1 p.
artikel
7 CN2 ECONOMIC EVALUATION OF NEW POLY-CHEMOTHERAPY REGIMENS AS ALTERNATIVES TO CISPLATIN PLUS PACLITAXEL IN ADVANCED NON-SMALL CELL LUNG CANCER Neymark, N
2002
5 6 p. 443-444
2 p.
artikel
8 CN3 IMMUNOTHERAPY WITH AUTOLOGOUS TUMOR CELL-BCG VACCINE (ONCOVAX®) IN PATIENTS WITH STAGE II COLON CANCER: MEDICAL AND ECONOMIC BENEFITS Uyl-de Groot, CA
2002
5 6 p. 444-
1 p.
artikel
9 CP3 CLAIMS BASED MEASURES OF DRUG TAKING COMPLIANCE AMONG MEDICAID PATIENTS WITH SCHIZOPHRENIA: FEASIBILITY AND PREDICTIVE UTILITY Christensen, DB
2002
5 6 p. 451-452
2 p.
artikel
10 CP1 CROSS-CULTURAL DIFFERENCES IN NONADHERENT ATTITUDES Bolge, SC
2002
5 6 p. 450-451
2 p.
artikel
11 CP2 THE IMPACT OF VARYING DEGREES OF COMPLIANCE WITH OSTEOPOROSIS MEDICATION ON FRACTURE RATES IN ACTUAL PRACTICE Caro, JJ
2002
5 6 p. 451-
1 p.
artikel
12 CV1 COST-EFFECTIVENESS OF FONDAPARINUX VS ENOXAPARIN AS PROPHYLAXIS AGAINST VENOUS THROMBOEMBOLISM FOLLOWING ORTHOPAEDIC SURGERY Posnett, J
2002
5 6 p. 444-
1 p.
artikel
13 CV2 ESTIMATION OF EXPENDITURES FOR CORONARY HEART DISEASE (CHD) IN GERMANY Wendland, G
2002
5 6 p. 444-445
2 p.
artikel
14 CV3 MULTI-COUNTRY COMPARISON OF HYPERTENSION COSTS FROM HOSPITALIZATIONS AND AMBULATORY CARE Mullins, CD
2002
5 6 p. 445-
1 p.
artikel
15 DISCLOSURE INFORMATION 2002
5 6 p. 591-598
8 p.
artikel
16 HP3 A RISK-ADJUSTED LEAGUE TABLE OF EXPECTED RETURNS Sendi, P
2002
5 6 p. 450-
1 p.
artikel
17 HP1 EFFICIENT PRODUCTION OF HEALTH BENEFITS: COST-EFFECTIVENESS EVIDENCE AND UTILISATION OF HEALTH TECHNOLOGY IN THE UK Benedict, Á
2002
5 6 p. 449-450
2 p.
artikel
18 HP2 HEALTH ECONOMIC EDUCATION IN ALLOCATION DECISIONS:A PRE-TEST POST-TEST STUDY Evans, CJ
2002
5 6 p. 450-
1 p.
artikel
19 HS1 COST-EFFECTIVENESS AND BUDGET IMPACT OF THE SIROLIMUS-ELUTING STENT IN THE STENT ERA Marchetti, M
2002
5 6 p. 457-
1 p.
artikel
20 HS2 COST-EFFECTIVENESS OF LEUKODEPLETION IN MAJOR CARDIAC SURGERY Van Hulst, M
2002
5 6 p. 457-
1 p.
artikel
21 HS3 ECONOMIES OF SCALE IN INTENSIVE CARE UNITS Rapoport, J
2002
5 6 p. 458-
1 p.
artikel
22 IN1 A BAYESIAN APPROACH TO NET HEALTH BENEFITS:AN ILLUSTRATION AND APPLICATION TO MODELING HIV PREVENTION Johnson-Masotti, A
2002
5 6 p. 445-446
2 p.
artikel
23 IN2 COST-EFFECTIVENESS (CE) OF SCREENING DONATED BLOOD WITH MINIPOOL NUCLEIC ACID TESTING (NAT) FOR HEPATITIS B VIRUS (HBV), HEPATITIS C VIRUS (HCV), AND HUMAN IMMUNODEFICIENCY VIRUS (HIV) Grima, DT
2002
5 6 p. 446-
1 p.
artikel
24 IN4 DISCOUNTING HEALTH BENEFITS:A NOVEL APPROACH TO ENSURE PROPER VALUING OF VACCINATION STRATEGIES Bos, JM
2002
5 6 p. 453-
1 p.
artikel
25 IN5 ECONOMIC EVALUATION OF A LARGE-SCALE MENINGOCOCCAL C VACCINATION PROGRAM IN THE NETHERLANDS Welte, R
2002
5 6 p. 453-454
2 p.
artikel
26 IN3 METHODS FOR ASSESSING COSTS AND EFFECTS OF ANTIRETROVIRAL THERAPIES IN HIV:THE IMPACT OF USING AN EXTENDED STUDY PERIOD Bos, JM
2002
5 6 p. 446-447
2 p.
artikel
27 IN6 PRIMARY CARE PRESCRIBING AND ANTIBIOTIC RESISTANCE:WHAT IS THE ADDED VALUE OF PERSON SPECIFIC DATA ABOUT ANTIBIOTIC PRESCRIBING COMPARED WITH EXISTING, PRACTICE LEVEL INFORMATION? Davey, PG
2002
5 6 p. 454-
1 p.
artikel
28 MC2 A COST-EFFECTIVENESS ANALYSIS OF ORAL TRIPTAN THERAPIES Yalkowsky, RB
2002
5 6 p. 455-
1 p.
artikel
29 MC1 DEVELOPMENT OF A FUNCTIONAL ASSESSMENT IN MIGRAINEURS MEASUREMENT TOOL BASED ON THE WHO'S ICIDH2 CLASSIFICATION Pathak, D
2002
5 6 p. 454-455
2 p.
artikel
30 MC3 PROJECTIONS FOR COPD IN THE NETHERLANDS: HOW THE TYPE OF PROJECTION AFFECTS THE ESTIMATED GROWTH IN PREVALENCE Feenstra, TL
2002
5 6 p. 455-
1 p.
artikel
31 MD4 CHANGES IN COST-EFFECTIVENESS OVER TIME:THE CASE OF EPOETIN ALFA FOR RENAL REPLACEMENT THERAPY PATIENTS IN THE UK Remak, E
2002
5 6 p. 458-
1 p.
artikel
32 MD2 MEASURING HEALTH IMPACTS ON WORK PERFORMANCE: COMPARING SUBJECTIVE AND OBJECTIVE REPORTS Pransky, G
2002
5 6 p. 448-449
2 p.
artikel
33 MD5 SHOULD THE EUROQOL DESCRIPTIVE SYSTEM BE EXTENDED FROM THREE TO FIVE LEVELS? A METHODOLOGICAL STRATEGY WITH AN EMPIRICAL PILOT Janssen, MF
2002
5 6 p. 458-459
2 p.
artikel
34 MD1 THE EQUITY-EFFICIENCY TRADEOFF:WHAT IS THE SOCIAL INTERPRETATION OF EQUITY? Pickee, S
2002
5 6 p. 448-
1 p.
artikel
35 MD3 VALIDATING A DISEASE MODEL ACCORDING TO CRITERIA OF EVIDENCE BASED MEDICINE Schramm, W
2002
5 6 p. 449-
1 p.
artikel
36 MD6 WHAT IS “TIME” IN TIME PREFERENCE STUDIES? Meerding, WJ
2002
5 6 p. 459-
1 p.
artikel
37 OD2 LONG-ACTING RISPERIDONE IN SCHIZOPHRENIC PATIENTS COMPARED WITH ORAL OLANZAPINE AND HALOPERIDOL DECANOATE:A COST-EFFECTIVENESS ANALYSIS Llorca, PM
2002
5 6 p. 456-
1 p.
artikel
38 OD3 STOCHASTIC COST-EFFECTIVENESS ANALYSIS OF CHRONIC VENOUS LEG ULCERS—THE CASE OF PROMOGRAN® IN A SWEDISH HEALTH CARE SETTING Ghatnekar, O
2002
5 6 p. 456-457
2 p.
artikel
39 OD1 THE COST-EFFECTIVENESS OF RALOXIFENE COMPARED WITH NO DRUG THERAPY FOR THE PREVENTION OF OSTEOPOROTIC FRACTURES WHEN HRT IS INAPPROPRIATE: THE CASE OF AUSTRALIA Davey, P
2002
5 6 p. 455-456
2 p.
artikel
40 PAR6 ANALYSIS OF CONSUMPTION OF NONSTEROID ANTIINFLAMMATORY DRUGS (GROUP M01) AT NATIONAL LEVEL IN DDD/1000/DAY: 1999–2001 Borissov, BN
2002
5 6 p. 477-
1 p.
artikel
41 PAR5 DISEASE SEVERITY AND COSTS AMONG PATIENTS STARTING A TREATMENT WITH COX-2 SPECIFIC INHIBITORS VERSUS NSAIDS PATIENTS IN ITALY: QUANTITATIVE ASSESSMENT IN 442 PATIENTS WITH ARTHRITIS Lucioni, C
2002
5 6 p. 476-477
2 p.
artikel
42 PAR7 MODELLED COST-EFFECTIVENESS AND COSTUTILITY ANALYSIS OF VARIOUS TREATMENT STRATEGIES IN OSTEOPOROTIC POSTMENOPAUSAL WOMEN IN POLAND Orlewska, E
2002
5 6 p. 477-
1 p.
artikel
43 PAR1 PHARMACOECONOMIC ANALISIS OF THE TREATMENT WITH LEFLUNOMIDEMETHOTREXATE OR INFLIXIMABMETHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS RESISTANT TO METHOTREXATE Rubio Terrés, C
2002
5 6 p. 475-
1 p.
artikel
44 PAR2 THE COST-EFFECTIVENESS ANALYSIS OF CELECOXIB AND NSAIDS WITH GASTROPROTECTIVE AGENTS FOR TREATMENT OF RHEUMATOID ARTHRITIS IN UKRAINE Zaliska, O
2002
5 6 p. 475-
1 p.
artikel
45 PAR3 VARIATION IN RESOURCE UTILIZATION AND TREATMENT COSTS FOR RHEUMATOID ARTHRITIS (RA) ACROSS 5 COUNTRIES IN AN ADALIMUMAB (D2E7) CLINICAL TRIAL Van de Putte, L
2002
5 6 p. 475-476
2 p.
artikel
46 PCN16 A COMPARISON OF THE COSTS OF GEMCITABINE/CISPLATIN AND GEMCITABINE/CARBOPLATIN COMBINATION REGIMENS IN THE TREATMENT OF ADVANCED NSCLC IN THE UK AND FRANCE Tilden, DP
2002
5 6 p. 542-
1 p.
artikel
47 PCN15 ANEMIA RESULTS IN INCREASED UTILIZATION IN CANCER PATIENTS Gupta, S
2002
5 6 p. 542-
1 p.
artikel
48 PCN8 AVERAGE TOTAL COST OF TREATING ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS IN SPAIN USING VARIOUS CHEMOTHERAPY DOUBLETS Kielhorn, A
2002
5 6 p. 539-
1 p.
artikel
49 PCN21 CANCER CHEMOTHERAPY AT HOME: FEASIBILITY, PATIENT OUTCOMES, AND HEALTHCARE SYSTEM IMPLICATIONS Boothroyd, LJ
2002
5 6 p. 544-545
2 p.
artikel
50 PCN5 COMPARING THE COST-EFFECTIVENESS OF FRONT-LOADED DARBEPOETIN ALFA WITH EPOETIN ALFA FOR ANEMIA MANAGEMENT IN CHEMOTHERAPY-TREATED CANCER PATIENTS IN UNITED STATES Glaspy, J
2002
5 6 p. 538-
1 p.
artikel
51 PCN17 COMPARING THE COST-EFFECTIVENESS OF 3 MCG/KG Q2W DARBEPOETIN ALFA WITH STANDARD DOSE EPOETIN ALFA FOR ANEMIA MANAGEMENT IN CHEMOTHERAPY-TREATED CANCER PATIENTS IN UNITED STATES Glaspy, J
2002
5 6 p. 543-
1 p.
artikel
52 PCN10 COST ANALYSIS OF CAPECITABINE VERSUS 5-FU/LV FOR COLORECTAL CANCER PATIENTS IN THE NETHERLANDS Postma, MJ
2002
5 6 p. 540-
1 p.
artikel
53 PCN1 COST ANALYSIS OF HLA-IDENTICAL SIBLING AND VOLUNTARY UNRELATED ALLOGENEIC BONE MARROW AND PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN ADULTS WITH ACUTE MYELOCYTIC LEUKAEMIA OR ACUTE LYMPHOBLASTIC LEUKAEMIA Groot, MT
2002
5 6 p. 536-
1 p.
artikel
54 PCN2 COST-EFFECTIVENESS OF NEW CERVICAL CANCER SCREENING TECHNOLOGIES:A GERMAN HEALTH TECHNOLOGY ASSESSMENT AND DECISION-ANALYSIS Sroczynski, G
2002
5 6 p. 536-537
2 p.
artikel
55 PCN9 COST-EFFICACY OF ZOLEDRONIC 4MG ACID VS. PAMIDRONATE 90MG IN THE TREATMENT OF HYPERCALCEMIA OF MALIGNACY (HCM) Badia, X
2002
5 6 p. 539-540
2 p.
artikel
56 PCN18 DERIVING A UTILITY WEIGHTED INDEX FROM CONDITION-SPECIFIC MEASURES: PRACTICAL SOLUTIONS FOR ECONOMIC EVALUTIONS Kind, P
2002
5 6 p. 543-
1 p.
artikel
57 PCN6 ECONOMICAL EVALUATION OF RALTITREXED VERSUS FLUOROURACIL PLUS LEUCOVORIN (5-FU + LV) FOR TREATMENT OF ADVANCED COLORECTAL CANCER Vorobyov, P
2002
5 6 p. 538-
1 p.
artikel
58 PCN19 EXAMINING PREFERENCES AND TIMETRADE-OFF UTILITY FOR GEMCITABINE PLUS CISPLATIN IN THE TREATMENT OF BLADDER CANCER:A SURVEY USING DISCRETE CHOICE CONJOINT ANALYSIS IN THE UK Brown, A
2002
5 6 p. 543-544
2 p.
artikel
59 PCN13 GEMZAR RETROSPECTIVE ECONOMIC ANALYSIS OF CLINICAL TRIALS (GREAT) IN THE TREATMENT OF NON-SMALL-CELL LUNG CANCER:A MULTI-COUNTRY COSTMINIMISATION ANALYSIS Aristides, M
2002
5 6 p. 541-
1 p.
artikel
60 PCN12 IMPACT OF INNOVATIVE AND EXPENSIVE THERAPIES IN THE TREATMENT OF METASTATIC BREAST CANCER (MBC): FOCUS ON TRASTUZUMAB (HERCEPTIN(H)) Miadi-Fargier, H
2002
5 6 p. 541-
1 p.
artikel
61 PCN4 IN THE UK GEMZAR DOUBLET HAS LOWEST TOTAL TREATMENT COSTS FOR NSCLC COMPARED TO FOUR OTHER CHEMOTHERAPY DOUBLETS Aristides, M
2002
5 6 p. 541-542
2 p.
artikel
62 PCN20 IS THERE DIFFERENCE BETWEEN GEMCITABINE BASED NSCLC TREATMENT AND OTHER PLATINUM BASED COMBINATIONS FOR RESPONSE RATES AND TOXICITY? Bhalla, S
2002
5 6 p. 544-
1 p.
artikel
63 PCN7 MAJOR DETERMINANTS OF COST IN ADVANCED NON-SMALL-CELL LUNG CANCER CHEMOTHERAPY REGIMES IN FRANCE Tilden, D
2002
5 6 p. 538-539
2 p.
artikel
64 PCN4 ONCE-PER-CYCLE FIXED-DOSE ADMINISTRATION OF PEGFILGRASTIM REDUCED RESOURCE UTILIZATION AND COSTS COMPARED WITH DAILY FILGRASTIM IN THE PREVENTION OF CHEMOTHERAPYINDUCED NEUTROPENIA Green, MD
2002
5 6 p. 537-538
2 p.
artikel
65 PCN11 PROPENSITY ANALYSIS OF EPOETIN USE AND ITS IMPACT ON OVERALL COSTS OF CANCER CARE Marchetti, M
2002
5 6 p. 540-541
2 p.
artikel
66 PCV31 ACCEPTANCE AND RELIABILITY OF A COSTMEASUREMENT QUESTIONNAIRE IN CARDIAC REHABILITATION Schweikert, B
2002
5 6 p. 489-490
2 p.
artikel
67 PCV20 A COST EFFECTIVENESS ANALYSIS OF SPIRONOLACTONE IN THE MANAGEMENT OF PATIENTS WITH SEVERE CHRONIC HEART FAILURE (CHF) IN THE IRISH HEALTHCARE SETTING Tilson, L
2002
5 6 p. 485-
1 p.
artikel
68 PCV56 ALLOCATION OF RESOURCES BETWEEN SMOKING CESSATION METHODS AND PHARMACEUTICAL TREATMENT OF HYPERCHOLESTEROLEMIA BASED ON COST-EFFECTIVENESS AND THE SOCIAL WELFARE FUNCTION Plans-Rubió, P
2002
5 6 p. 499-
1 p.
artikel
69 PCV1 AN ECONOMIC EVALUATION OF CLOPIDOGREL IN SECONDARY PREVENTION OF ISCHEMIC EVENTS: HIGH RISK POPULATIONS Levy, E
2002
5 6 p. 477-478
2 p.
artikel
70 PCV22 A PHARMACOECONOMIC EVALUATION OF AGGRESSIVE LIPID-LOWERING THERAPY COMPARED WITH ANGIOPLASTY IN STABLE CORONARY ARTERY DISEASE IN SPAIN Domingo, E
2002
5 6 p. 486-
1 p.
artikel
71 PCV39 A REVIEW OF THE PHARMACOTHERAPEUTIC MANAGEMENT OF PULMONARY ARTERIAL HYPERTENSION Richard, LJ
2002
5 6 p. 492-493
2 p.
artikel
72 PCV40 COMORBIDITIES CAUSING INCREASING MORTALITY AT AGES UNDER 65 IN CARDIOVASCULAR DISEASE AND HYPERTENSION Farquhar, IV
2002
5 6 p. 493-
1 p.
artikel
73 PCV27 COMPARING RESOURCE USE INTENSITY IN THREE POPULATIONS WITH ATHEROTHROMBOSIS Migliaccio-Walle, K
2002
5 6 p. 488-
1 p.
artikel
74 PCV46 CORRELATES OF SATISFACTION WITH PAIN CONTROL AMONG CARDIOVASCULAR PATIENTS IN THE US (2001) Wolosin, RJ
2002
5 6 p. 495-
1 p.
artikel
75 PCV12 COST-EFFECTIVENES OF ENOXAPARIN AS THROMBOPROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS IN BRAZIL Nuijten, MJC
2002
5 6 p. 482-
1 p.
artikel
76 PCV4 COST-EFFECTIVENESS ANALYSIS OF N-3 POLYUNSATURED FATTY ACIDS (PUFA) AFTER MYOCARDIAL INFARCTION, FRENCH ASSESSMENT Taïeb, C
2002
5 6 p. 479-
1 p.
artikel
77 PCV17 COST-EFFECTIVENESS ANALYSIS OF TREATMENTS TO REDUCE CHOLESTEROL CONCENTRATION, BLOOD PRESSURE AND SMOKING FOR THE PREVENTION OF CORONARY HEART DISEASE Plans-Rubió, P
2002
5 6 p. 484-
1 p.
artikel
78 PCV33 COST-EFFECTIVENESS OF METHODS TO QUIT SMOKING IN FINNISH HEALTH CARE Jormanainen, VJ
2002
5 6 p. 490-
1 p.
artikel
79 PCV34 COST-EFFECTIVENESS OF PATHOGEN INACTIVATION FOR PLATELET TRANSFUSIONS IN DUTCH CARDIAC SURGERY Postma, MJ
2002
5 6 p. 490-491
2 p.
artikel
80 PCV24 COST-EFFECTIVENSS OF ANTICOAGULATION MANAGEMENT IN TWO MODELS OF CARE You, JH
2002
5 6 p. 487-
1 p.
artikel
81 PCV5 COST IMPACT OF AMLODIPINE IN BRITISH COLUMBIA BASED ON THE PREVENT TRIAL RESULTS Ali, F
2002
5 6 p. 479-
1 p.
artikel
82 PCV13 COST OF MANAGING UNSTABLE ANGINA PATIENTS OVER A NINE-MONTH PERIOD:A EUROPEAN APPROACH Gabriel, S
2002
5 6 p. 482-
1 p.
artikel
83 PCV10 COST OF UNCONTROLLED HYPERTENSION IN CANADA Ali, F
2002
5 6 p. 481-
1 p.
artikel
84 PCV35 COSTS OF STROKE:A COMPARISON OF REGULAR CARE AND THREE EXPERIMENTAL STROKE SERVICES IN THE NETHERLANDS Van Exel, J
2002
5 6 p. 491-
1 p.
artikel
85 PCV45 DETERMINANTS OF FIRST-YEAR QUALITY OF LIFE (QOL) AFTER SURGERY—INTERIM ANALYSIS OF A RANDOMISED TRIAL WITH LAPBAND-SURGERY AND VERTICAL BANDED GASTROPLASTY (VBG) Mastrigt van, G
2002
5 6 p. 495-
1 p.
artikel
86 PCV37 DOES COMPLIANCE WITH ACE-I, DIGOXIN AND SPIRONOLACTONE INFLUENCE THE TIME TO EVENT IN PATIENTS WITH HEART FAILURE? Gwadry-Sridhar, F
2002
5 6 p. 492-
1 p.
artikel
87 PCV14 ECONOMIC EVALUATION OF A COMPLIANCE PROGRAM IN PATIENTS WITH STATIN THERAPY—DESIGN AND PILOT PHASE OF THE ORBITAL STUDY Upmeier, H
2002
5 6 p. 483-
1 p.
artikel
88 PCV25 ECONOMIC EVALUATION OF PRIMARY PREVENTION OF CVD EVENTS WITH ATORVASTATIN:AN ITALIAN PERSPECTIVE Mantovani, LG
2002
5 6 p. 487-
1 p.
artikel
89 PCV7 ECONOMIC EVALUATION OF THE ATORVASTATIN VERSUS REVASCULARIZATION TREATMENT STUDY (AVERT):AN ITALIAN CUSTOMIZATION Ruffo, P
2002
5 6 p. 480-
1 p.
artikel
90 PCV8 ECONOMIC EVALUATION OF THE CORONARY ANGIOPLASTY AMLODIPINE RESTENOSIS STUDY (CAPARES):AN ITALIAN CUSTOMIZATION Bustacchini, S
2002
5 6 p. 480-
1 p.
artikel
91 PCV21 ECONOMIC EVALUATION OF THE PROSPECTIVE RANDOMIZED EVALUATION OF VASCULAR EFFECT OF NORVASC STUDY (PREVENT):AN ITALIAN CUSTOMIZATION Mantovani, LG
2002
5 6 p. 485-486
2 p.
artikel
92 PCV50 EVALUATION OF NITRATE PRESCRIPTION PATTERNS AMONG PHYSICIANS FROM DIFFERENT SPECIALITIES IN ISRAEL Reuveni, H
2002
5 6 p. 497-
1 p.
artikel
93 PCV57 IMPLICATIONS OF TREATMENT GUIDELINES: WHAT STATINS DO WE REALLY NEED? Haiderali, A
2002
5 6 p. 499-500
2 p.
artikel
94 PCV16 INCIDENCE AND ECONOMIC BURDEN OF DEEP VEIN THROMBOSIS AFTER TOTAL HIP REPLACEMENT IN HONG KONG Lee, KK
2002
5 6 p. 483-484
2 p.
artikel
95 PCV53 INFLUENCE OF THREE HYPERTENSION GUIDELINES ON RATES OF TREATMENT INDICATION Rosery, H
2002
5 6 p. 498-
1 p.
artikel
96 PCV43 IS THERE ANY RELATIONSHIP BETWEEN COMPLIANCE AND HRQOL IN PATIENTS WITH HEART FAILURE? Gwadry-Sridhar, F
2002
5 6 p. 494-
1 p.
artikel
97 PCV38 LIPID LOWERING MEDICATIONS FOLLOWING CORONARY REVASCULARIZATION PROCEDURES Brophy, J
2002
5 6 p. 492-
1 p.
artikel
98 PCV52 LOW LEVEL OF CONSISTENCY BETWEEN QUALITATIVE (NCEP-II) AND QUANTITATIVE METHODS TO RECOMMEND PHARMACEUTICAL TREATMENT OF HYPERCHOLESTEROLEMIA IN INDIVIDUALS WITHOUT CORONARY HEART DISEASE Plans-Rubió, P
2002
5 6 p. 498-
1 p.
artikel
99 PCV15 MANAGEMENT EFFECTIVENESS AND COST/UTILITY RATIO IN CHRONIC HEART FAILURE: COMPARISON BETWEEN HEART FAILURE MANAGEMENT PROGRAM DELIVERED BY DAY-HOSPITAL AND USUAL CARE Capomolla, S
2002
5 6 p. 483-
1 p.
artikel
100 PCV36 OBESITY AND POTENTIAL COST OFFSETS FROM WEIGHT LOSS—FINDINGS FROM THE SWEDISH MALMO PREVENTION STUDY Persson, U
2002
5 6 p. 491-492
2 p.
artikel
101 PCV9 OUTCOMES AND COSTS OF THROMBOPROPHYLAXIS WITH LOWMOLECULAR WEIGHT HEPARIN IN ACUTELYILL MEDICAL INPATIENTS Thompson, D
2002
5 6 p. 481-
1 p.
artikel
102 PCV28 PERSISTENCE WITH ANTIHYPERTENSIVE DRUG TREATMENT:AN EVALUATION BASED ON A BAYESIAN COST-EFFECTIVENESS APPROACH Baio, G
2002
5 6 p. 488-
1 p.
artikel
103 PCV23 PHARMACOECONOMIC COMPARISON OF THE ANTIHYPERTENSIVE TREATMENT WITH TWO DIFFERENT ANGIOTENSINE CONVERTING ENZYME INHIBITORS: PERINDOPRIL AND ENALAPRIL Hermanowski, T
2002
5 6 p. 486-487
2 p.
artikel
104 PCV2 PHYSICIAN CHARACTERISTICS OF THE NAVIGATOR TRIAL PREDICT AVERAGE LENGTH OF STAY (ALOS) IN ACUTE CORONARY SYNDROME (ACS) Friedman, JY
2002
5 6 p. 478-
1 p.
artikel
105 PCV51 POSSIBILITIES OF NEW TECHNOLOGIES AMONG PATIENTS WITH HYPERTENSION: FEASIBILITY AND ACCEPTANCE OF AN EDUCATIVE INTERVENTION THROUGH SHORT MESSAGES TO THE PATIENT'S CELLULAR PHONE De la Figuera, M
2002
5 6 p. 497-
1 p.
artikel
106 PCV30 PROBABILISTIC SENSITIVITY ANALYSIS FOR EVALUATING COST-EFFECTIVENESS IN SECONDARY PREVENTION OF ISCHEMIC EVENTS Lennes, X
2002
5 6 p. 489-
1 p.
artikel
107 PCV58 RANDOMIZED CONTROLLED INTERVENTION IN CARDIOVASCULAR DRUG TREATMENT IN NURSING HOMES Ulfvarson, J
2002
5 6 p. 500-
1 p.
artikel
108 PCV11 RESOURCE UTILIZATION DURING THE FOUR MONTHS FOLLOWING A DIAGNOSIS OF DEEP VENOUS THROMBOSIS Kahn, SR
2002
5 6 p. 481-482
2 p.
artikel
109 PCV41 SCREENING FOR ANEURYSMS AFTER SUCCESSFUL TREATMENT FOR SUBARACHNOID HAEMORRHAGE: DO WE HAVE THE EVIDENCE? Buskens, E
2002
5 6 p. 493-494
2 p.
artikel
110 PCV54 SMOKING CESSATION: RELEVANCE IN THE UNDER 25 GROUP Taïeb, C
2002
5 6 p. 498-499
2 p.
artikel
111 PCV55 SMOKING DEPENDENCY:AUDIT CARRIED OUT AMONG THE UNDER 25 GROUP Taïeb, C
2002
5 6 p. 499-
1 p.
artikel
112 PCV18 SOCIOECONOMIC RELEVANCE OF TREATMENT OF CHRONIC HEART FAILURE STAGE NYHA II WITH CRATAEGUS EXTRACT WS® 1442— TWO-YEAR-RESULTS OF A PROSPECTIVE PHARMACOECONOMIC STUDY Rychlik, R
2002
5 6 p. 484-485
2 p.
artikel
113 PCV47 THE ASSESSMENT OF THE INFLUENCE OF AN EDUCATIONAL INTERVENTION ON PATIENT IMPORTANT OUTCOMES INCLUDING HEALTH RELATED QUALITY OF LIFE (HRQOL) AND MORTALITY USING A TIME-TO-EVENT SURVIVAL ANALYSIS IN PATIENTS WITH HEART FAILURE Gwadry-Sridhar, F
2002
5 6 p. 496-
1 p.
artikel
114 PCV6 THE COST COMPARISON OF CARDIOVERSION AND ANTIARRHYTHMIC THERAPY IN NONVALVULAR CHRONIC ATRIAL FIBRILLATION Pietrasik, AL
2002
5 6 p. 479-480
2 p.
artikel
115 PCV29 THE COST-EFFECTIVENESS OF DIAGNOSTIC STRATEGIES WITH ANGIOGRAPHY AND/OR DUPLEX SCANNING FOR AORTOILIAC AND FEMOROPOPLITEAL ARTERIAL DISEASE Coffi, S
2002
5 6 p. 489-
1 p.
artikel
116 PCV26 THE HEALTH ECONOMIC IMPLICATIONS OF TREATING ANEMIA IN PATIENTS WITH CONGESTIVE HEART FAILURE Caro, J
2002
5 6 p. 487-488
2 p.
artikel
117 PCV44 THE IMPACT OF AN EDUCATIONAL INTERVENTION ON MULTIPLE HEALTH REALTED QUALITY OF LIFE MEASURES IN PATIENTS WITH HEART FAILURE (HF) Gwadry-Sridhar, F
2002
5 6 p. 494-495
2 p.
artikel
118 PCV49 THE INFLUENCE OF COPAYMENTS ON THE DEMAND FOR DRUGS WITH THERAPEUTIC COMPETITORS:THE STATINS Esposito, D
2002
5 6 p. 496-497
2 p.
artikel
119 PCV32 THE USE OF STATINS IN SECONDARY CARE: EVIDENCE FROM ACTUAL PRACTICE DATA Degli Esposti, L
2002
5 6 p. 490-
1 p.
artikel
120 PCV19 TWO METHODS OF ASSESSING COSTS OF PHARMACOLOGICAL TREATMENT ASSOCIATED WITH CHRONIC VENOUS INSUFFICIENCY (CVI) IN POLAND Czech, M
2002
5 6 p. 485-
1 p.
artikel
121 PCV42 UNCERTAINTIES IN COST-EFFECTIVENESS EVALUATION OF CAROTID ANGIOPLASTY AND STENTING Janssen, MP
2002
5 6 p. 494-
1 p.
artikel
122 PCV48 WHAT IS THE WILLINGNESS TO PAY FOR FUTURE HEALTH BENEFITS AMONG HYPERTENSIVE PATIENTS—A PILOT STUDY IN POLISH SETTING Czech, M
2002
5 6 p. 496-
1 p.
artikel
123 PDB10 A CROSS-OVER RANDOMISED CONTROLLED TRIAL TO COMPARE PSYCHOLOGICAL BARRIERS TO INSULIN SELF-INJECTION WITH THE INNOLET AND VIAL/SYRINGE Skovlund, SE
2002
5 6 p. 549-
1 p.
artikel
124 PDB2 COST-EFFECTIVENESS ANALYSIS OF GLYCEMIC CONTROL WITH PIOGLITAZONE HYDROCHLORIDE FOR JAPANESE PATIENTS WITH TYPE II DIABETES Ikeda, S
2002
5 6 p. 545-
1 p.
artikel
125 PDB1 COST-EFFECTIVENESS OF SWITCHING PATIENTS TO COMBINED GLIBENCLAMIDE AND METFORMIN (GLUCOVANCE) WHEN POORLY CONTROLLED WITH METFORMIN MONOTHERAPY:THE FRENCH PERSPECTIVE Roze, S
2002
5 6 p. 545-
1 p.
artikel
126 PDB9 DEVELOPMENT AND VALIDATION OF THE INSULIN TREATMENT SATISFACTION QUESTIONNAIRE (ITSQ) Anderson, RT
2002
5 6 p. 548-
1 p.
artikel
127 PDB3 INTENSIVE LIFESTYLE CHANGES OR METFORMIN IN OVERWEIGHT, GLUCOSE INTOLERANT PATIENTS: MODELING THE LONG-TERM HEALTH ECONOMICS IMPLICATIONS OF THE DIABETES PREVENTION PROGRAM IN THE FRENCH, GERMAN, AND UK SETTINGS Palmer, AJ
2002
5 6 p. 545-546
2 p.
artikel
128 PDB5 LONG-TERM CONSEQUENCES FOR THE TREATMENT OF HYPERTENSIVE DIABETES TYPE 2 PATIENTS WITH A FIXED COMBINATION OF AN ACE-INHIBITOR AND NON-DIHYDROPYRIDINE-CALCIUM-CHANNELBLOCKER IN COMPARISON TO OTHER COMBINATION THERAPIES Maxion-Bergemann, S
2002
5 6 p. 546-547
2 p.
artikel
129 PDB14 MEDICAID MANAGED CARE QUALITY AMONG BLACK AND WHITE ADULTS WITH DIABETES MELLITUS Mayberry, RM
2002
5 6 p. 550-
1 p.
artikel
130 PDB13 REAL WORLD ADHERENCE BENEFITS FROM COMBINATION PRODUCTS UTILIZED IN DIABETICS: SULFONYLUREAS & METFORMIN Schaffer, M
2002
5 6 p. 550-
1 p.
artikel
131 PDB6 RETROSPECTIVE STUDY EVALUATING CLINICAL AND ECONOMIC OUTCOMES OF MONOTHERAPY VERSUS DUAL THERAPY IN DIABETIC PATIENTS IN A COUNTY HEALTH CARE SYSTEM Lal, LS
2002
5 6 p. 547-
1 p.
artikel
132 PDB9 SELF-ASSESSMENT OF DIABETES CONTROL: ACCURACY OF PATIENTS' PERCEPTIONS Bolge, SC
2002
5 6 p. 549-550
2 p.
artikel
133 PDB4 THE HEALTH-ECONOMIC IMPLICATIONS OF THE “IRBESARTAN IN DIABETIC NEPHROPATHY TRIAL” (IDNT) IN FRANCE AND BELGIUM Palmer, AJ
2002
5 6 p. 546-
1 p.
artikel
134 PDB7 THE WHO/IDF CARECARD DIABETES AS AN INTERNET-BASED APPROACH FOR QUALITY ASSURANCE IN SWITZERLAND Schramm, W
2002
5 6 p. 547-548
2 p.
artikel
135 PDB8 TYPE-2 DIABETES AND BODY MASS INDEX (BMI):WHAT CAN WE LEARN FROM A LONGITUDINAL DATABASE STUDY? Charpentier, G
2002
5 6 p. 548-
1 p.
artikel
136 PDB11 TYPE 1 DIABETES, LONG-TERM COMPLICATIONS AND QUALITY OF LIFE MEASURED WITH RAND-36 HEALTH PROFILE MEASURE Hahl, J
2002
5 6 p. 549-
1 p.
artikel
137 PDB15 USE OF THE PATIENT ANALYSIS & TRACKING SYSTEM (PATS) IN ASSESSMENT OF RATIONAL PHARMACOTHERAPY OF DIABETICS IN A BIG HOSPITAL Sechser, T
2002
5 6 p. 551-
1 p.
artikel
138 PES4 A DISEASE SEVERITY STAGING SYSTEM FOR MEASURING THE COST OF GLAUCOMA PROGRESSION IN EUROPE Doyle, J
2002
5 6 p. 552-
1 p.
artikel
139 PES25 ASSESSMENT OF THE DERMATOLOGIC LIFE QUALITY INDEX (DLQI) IN CHRONIC IDIOPATHIC URTICARIA Lennox, R
2002
5 6 p. 560-
1 p.
artikel
140 PES12 BURDEN OF ATOPIC DERMATITIS IN SWITZERLAND Kugland, B
2002
5 6 p. 555-
1 p.
artikel
141 PES9 COST-EFFECTIVENESS AND COST-UTILITY OF OLOPATADINE IN THE TREATMENT OF SEASONAL ALLERGIC CONJUNCTIVITIS (SAC) IN 6 EUROPEAN COUNTRIES Lilliu, H
2002
5 6 p. 554-
1 p.
artikel
142 PES1 COST EFFECTIVENESS OF PIMECROLIMUS (ELIDEL) IN THE TREATMENT OF CHILDREN WITH ATOPIC DERMATITIS Grueger, J
2002
5 6 p. 556-
1 p.
artikel
143 PES1 COST OF ILLNESS OF GLAUCOMA IN CANADA: ANALYSES BASED ON VISUAL FIELD MEASUREMENTS AND PHYSICIAN'S ASSESSMENT Iskedjian, M
2002
5 6 p. 551-
1 p.
artikel
144 PES5 COST-UTILITY ANALYSIS OF TIMOLOL VERSUS LATANOPROST VERSUS TRAVOPROST IN THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION Lilliu, H
2002
5 6 p. 552-553
2 p.
artikel
145 PES7 COST-UTILITY OF VITAMINS FOR THE TREATMENT OF MACULAR DEGENERATION Sharma, S
2002
5 6 p. 553-554
2 p.
artikel
146 PES20 DERIVATION OF SYMPTOMS SCORES AND QOL SCORES FROM CLINICAL DATA IN SEASONAL ALLERGIC CONJUNCTIVITIS Le Pen, C
2002
5 6 p. 558-559
2 p.
artikel
147 PES11 ECONOMIC EVALUATION OF METHOTREXATE AND CYCLOSPORIN A FOR PATIENTS WITH SEVERE PSORIASIS Opmeer, B
2002
5 6 p. 555-
1 p.
artikel
148 PES26 HEALTH STATE UTILITIES IN PATIENTS WITH DERMATOLOGICAL PROBLEMS—A POPULATION STUDY Bingefors, C
2002
5 6 p. 560-561
2 p.
artikel
149 PES22 IMPACT OF CHILDREN'S SKIN DISEASES ON THEIR PARENTS' QUALITY OF LIFE Taöeb, C
2002
5 6 p. 559-
1 p.
artikel
150 PES21 IMPACT OF HYDROTHERAPY CARES ON THE QUALITY OF LIFE OF PATIENTS' SUFFERING FROM SKIN DISEASES Taöeb, C
2002
5 6 p. 559-
1 p.
artikel
151 PES19 INITIAL DEVELOPMENT AND VALIDATION OF THE EYE ALLERGY PATIENT IMPACT QUESTIONNAIRE (EAPIQ) Buchholz, P
2002
5 6 p. 558-
1 p.
artikel
152 PES3 LIFE-LONG SOCIETAL NET VALUE OF GLAUCOMA TREATMENT:A MARKOV MODEL APPROACH Lafuma, A
2002
5 6 p. 552-
1 p.
artikel
153 PES8 LOW VISUAL ACUITY AND BLINDNESS SOCIAL COSTS IN FRANCE Lafuma, A
2002
5 6 p. 554-
1 p.
artikel
154 PES16 MEDICAL OUTCOME OF GLAUCOMA TREATMENT IN FRANCE Denis, P
2002
5 6 p. 557-
1 p.
artikel
155 PES2 MEDICAL PREDICTIVE FACTORS OF GLAUCOMA TREATMENT COSTS IN FRANCE Denis, P
2002
5 6 p. 551-552
2 p.
artikel
156 PES6 PATIENT REPORTED OUTCOMES AND HEATH SYSTEM ECONOMIC IMPACT OF A REFORMULATION TO IMPROVE BRIMONIDINE 0.2% PATIENT OUTCOMES Buchholz, PM
2002
5 6 p. 553-
1 p.
artikel
157 PES10 PHARMACOECONOMIC EVALUATION OF A NEW TWO COMPOUND OINTMENT (DAIVOBET®) AND CALCIPOTRIOL (DAIVONEX®) IN THE TREATMENT OF PSORIASIS VULGARIS IN SWEDEN Sørensen, M
2002
5 6 p. 554-555
2 p.
artikel
158 PES17 PSORIASIS AND DEPRESSIVE SYMPTOMATOLOGY Taöeb, C
2002
5 6 p. 557-
1 p.
artikel
159 PES23 PSORIASIS AND QUALITY OF LIFE SPANISH RESULTS Finlay, A
2002
5 6 p. 559-560
2 p.
artikel
160 PES24 PSORIASIS, QUALITY OF LIFE AND DEPRESSIVE SYMPTOMATOLOGY: FRENCH RESULTS Taöeb, C
2002
5 6 p. 560-
1 p.
artikel
161 PES13 RESOURCE UTILIZATION IN PATIENTS SUFFERING FROM ATOPIC DERMATITIS IN GERMANY Ehlken, B
2002
5 6 p. 555-556
2 p.
artikel
162 PES15 USING A DISCRIMINANT FUNCTION TO MODEL THE LONG-TERM VISUAL FIELD CONSEQUENCES OF IOP CONTROL:A CASE STUDY BASED ON A TIMOLOL, LATANOPROST AND TRAVOPROST CLINICAL TRIAL Nordmann, JP
2002
5 6 p. 556-557
2 p.
artikel
163 PES18 VISION RELATED QUALITY OF LIFE OF FRENCH PATIENTS IS AFFECTED BY TOPICAL GLAUCOMA TREATMENT SIDE EFFECTS Nordmann, J
2002
5 6 p. 557-558
2 p.
artikel
164 PGS5 A COST-EFFECTIVENESS ANALYSIS OF ESOMEPRAZOLE VS. OMEPRAZOLE IN THE ACUTE TREATMENT OF PATIENTS WITH REFLUX OESOPHAGITIS IN GREECE Karokis, A
2002
5 6 p. 502-
1 p.
artikel
165 PGS7 ANALYSIS OF RESOURCE USE AND COSTS ASSOCIATED WITH MINOR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAID) RELATED GASTRO-INTESTINAL (GI) EVENTS Annemans, L
2002
5 6 p. 503-
1 p.
artikel
166 PGS14 CORRELATION BETWEEN DIFFERENT PRODUCTIVITY VARIABLES OBTAINED FROM THE WPAI-GERD QUESTIONNAIRE Wahlqvist, P
2002
5 6 p. 505-506
2 p.
artikel
167 PGS6 COST COMPARISON OF ESOMEPRAZOLE BASED AND OMEPRAZOLE BASED HELICOBACTER PYLORI ERADICATION STRATEGIES IN DUODENAL ULCER DISEASE IN GREECE Christodoulopoulou, A
2002
5 6 p. 502-503
2 p.
artikel
168 PGS2 ECONOMIC BURDEN OF IBS Badia, X
2002
5 6 p. 501-
1 p.
artikel
169 PGS1 EMPLOYMENT LOSSES RELATED TO INFLAMMATORY BOWEL DISEASE IN THE UNITED STATES: RESULTS FROM THE NATIONAL INTERVIEW SURVEY Longobardi, T
2002
5 6 p. 500-
1 p.
artikel
170 PGS16 EVALUATION OF THE USE OF PROTON PUMP INHIBITORS IN A PUBLIC HOSPITAL IN HONG KONG Lee, VW
2002
5 6 p. 506-
1 p.
artikel
171 PGS15 FORMULARY CONVERSION OF PROTON PUMP INHIBITORS: MONITORING FOR POTENTIAL DRUG INTERACTION DeLattre, ML
2002
5 6 p. 506-
1 p.
artikel
172 PGS3 HEALTH CARE RESOURCE UTILIZATION AND COSTS OF TREATING NSAID-ASSOCIATED GASTROINTESTINAL TOXICITY IN JAPAN: FEASIBILITY OF A DELPHI-PANEL APPROACH IN JAPAN Kamae, I
2002
5 6 p. 501-
1 p.
artikel
173 PGS13 HEALTH STATE UTILITIES AND WILLINGNESS TO PAY IN GERD PATIENTS WITH HEARTBURN Kartman, B
2002
5 6 p. 505-
1 p.
artikel
174 PGS11 IMPACT OF IBS ON QUALITY OF LIFE AND PSYCHOLOGICAL WELL-BEING IN PATIENTS AND RELATIVES Badia, X
2002
5 6 p. 504-
1 p.
artikel
175 PGS12 IRRITABLE BOWEL SYNDROME (IBS) SIGNIFICANTLY AFFECTS PATIENT QUALITY OF LIFE (QOL) AND IS RESPONSIBLE FOR HIGH COSTS IN FRANCE:THE ENCOLI STUDY Brun-Strang, C
2002
5 6 p. 505-
1 p.
artikel
176 PGS4 LOW-DOSE PPI AND STANDARD-DOSE PPI COMPARED WITH H2RA FOR MAINTENANCE THERAPY OF GERD—A COST-EFFECTIVENESS ANALYSIS USING MARKOV MODEL You, JH
2002
5 6 p. 501-502
2 p.
artikel
177 PGS8 META-ANALYSIS OF ESOMEPRAZOLE 40MG AND LANSOPRAZOLE 30MG IN THE HEALING OF REFLUX OESOPHAGITIS Edwards, S
2002
5 6 p. 503-
1 p.
artikel
178 PGS9 OUTCOMES ANALYSIS OF RABEPRAZOLE (ACIPHEX) USE AT A VETERAN AFFAIRS MEDICAL CENTER Gordon, M
2002
5 6 p. 503-504
2 p.
artikel
179 PGS10 TOWARDS A MULTISTAGE DECISION ANALYSIS FOR THE TREATMENT OF FAECAL INCONTINENCE Dijkgraaf, M
2002
5 6 p. 504-
1 p.
artikel
180 PHP8 AN ECONOMIC MODEL FOR COOPERATION BETWEEN A NOT-FOR-PROFIT HMO AND A PHARMACEUTICAL COMPANY IN A DISEASE MANAGEMENT PROGRAM:TRANSFORMING CONFLICT OF INTERESTS INTO UTILITY MAXIMIZATION Shavit, O
2002
5 6 p. 467-
1 p.
artikel
181 PHP1 ASSESSMENT OF PROPOSED GUIDELINES FOR PHARMACOECONOMIC SUBMISSIONS IN GREECE: OVERVIEW AND IMPLEMENTATION PROBLEMS Geitona, M
2002
5 6 p. 464-
1 p.
artikel
182 PHP5 “AUT IDEM”—250 MILLION € SAVINGS P. A. FOR STATUARY HEALTH INSURANCE IN GERMANY? Pirk, O
2002
5 6 p. 465-466
2 p.
artikel
183 PHP26 CLASSIFICATION AND REGRESSION TREES HELP IN DEVELOPING EMBEDDED EVIDENCEAND CONSENSUS-BASED GUIDELINES Marchetti, M
2002
5 6 p. 474-
1 p.
artikel
184 PHP11 DESCRIPTIVE AND COMPARATIVE STUDY OF PATIENT-MANAGEMENT BY HOMEOPATHIC GPS VERSUS ALLOPATHIC GPS Vainchtock, A
2002
5 6 p. 468-
1 p.
artikel
185 PHP6 DRUG COSTS REGULATION SYSTEM IN THE SLOVAK REPUBLIC Tomek, D
2002
5 6 p. 466-
1 p.
artikel
186 PHP28 ECONOMIC STUDY OF MALNUTRITION IN ELDERLY PATIENTS LIVING IN THE COMMUNITY: USE OF PROPENSITY SCORE TO ANALYZE OBSERVATIONAL DATA Schmitt, C
2002
5 6 p. 474-475
2 p.
artikel
187 PHP18 ESTIMATING THE ECONOMIC BURDEN OF HOSPITALIZATION DUE TO PATIENT NONADHERENCE IN CANADA Iskedjian, M
2002
5 6 p. 470-471
2 p.
artikel
188 PHP16 GENERIC DRUG PRICES ARE TYPICALLY HIGHER IN CANADA THAN IN THE UNITED STATES Palmer, WN
2002
5 6 p. 470-
1 p.
artikel
189 PHP20 HARMONIZATION OF HOSPITAL COSTS Jacobs, P
2002
5 6 p. 471-472
2 p.
artikel
190 PHP19 HEALTH EXPENDITURE FOR THE DURATION OF LAST YEAR OF LIFE IN TAIWAN Liang, LY
2002
5 6 p. 471-
1 p.
artikel
191 PHP27 HEALTH STATE VALUATIONS IN SUMMARY MEASURES OF POPULATION HEALTH Salomon, J
2002
5 6 p. 474-
1 p.
artikel
192 PHP3 IMPROVING PATIENT ACCESS TO INNOVATION—THE NEW BELGIAN REIMBURSEMENT PROCEDURE Umbach, I
2002
5 6 p. 465-
1 p.
artikel
193 PHP12 INFLUENCING PRESCRIBING IN ENGLISH PRIMARY CARE: FINDINGS FROM THE MANMED SURVEY Mason, A
2002
5 6 p. 469-
1 p.
artikel
194 PHP14 MANAGING THERAPEUTICS NOVELTIES USING A SCIENTIFIC EVIDENCE-BASED METHOD Catalan, A
2002
5 6 p. 469-
1 p.
artikel
195 PHP25 METHODOLOGICAL ISSUES: RESOURCE-BASED ZERO WORK HOUR PROCEDURES IN U.S. PHYSICIANS' OFFICES Baker, JJ
2002
5 6 p. 473-
1 p.
artikel
196 PHP7 MODELLING, ECONOMIC EVALUATIONS, AND THE DEVELOPMENT OF CLINICAL PRACTICE GUIDELINES:A SURVEY OF 38 GUIDELINES IN THE NETHERLANDS Redekop, WK
2002
5 6 p. 466-
1 p.
artikel
197 PHP4 OUT-OF-POCKET PAYMENT IN BELGIUM:AN ANALYSIS IN RELATION TO PATHOLOGY Ooms, D
2002
5 6 p. 465-
1 p.
artikel
198 PHP9 RISK SHARING IN A STATE FUNDED HEALTH SERVICE: OUTCOMES GUARANTEE PROJECT Chapman, SR
2002
5 6 p. 467-
1 p.
artikel
199 PHP12 SELF-REPORTED PATIENT EXPERIENCE DATA, PROVIDED TO PHYSICIANS AT THE POINT-OFCARE, OFFERS AN IMPORTANT COMPLEMENT TO TRADITIONAL EFFICACY DATA AND ENABLES THE DERIVATION OF PRACTICEWIDE TREATMENT GUIDELINES Schmeichel, CJ
2002
5 6 p. 468-
1 p.
artikel
200 PHP17 SPANISH NATIONAL HEALTH SERVICE (NHS): PHARMACEUTICAL CONSUMPTION AND ESTIMATION OF THE SAVING WITH GENERIC DRUG PRESCRIPTIONS Gaspar, D
2002
5 6 p. 470-
1 p.
artikel
201 PHP23 THE CONTRIBUTION OF HEALTH ECONOMICS TO PORTFOLIO MANAGEMENT DECISIONS:A VACCINE INDUSTRY EXAMPLE Staginnus, U
2002
5 6 p. 472-473
2 p.
artikel
202 PHP15 THE USE OF PATHOLOGY-RELATED PARAMETERS IN EXPLAINING THE VARIATION OF PUBLIC EXPENDITURES ON MEDICAL IMAGING Puttevils, D
2002
5 6 p. 469-470
2 p.
artikel
203 PHP24 USE OF POLICY MODELING TO PROMOTE INFORMED DECISION MAKING: DEVELOPMENT AND APPLICATION OF THE CANADIAN STROKE POLICY MODEL Matchar, DB
2002
5 6 p. 473-
1 p.
artikel
204 PHP2 VARIABILITY IN EUROPEAN REIMBURSEMENT SCHEMES FOR ANTIBIOTICS: CONSEQUENCES FOR EUROPEAN SURVEILLANCE OF ANTIBIOTIC CONSUMPTION (ESAC PROJECT) Ferech, M
2002
5 6 p. 464-465
2 p.
artikel
205 PHP22 WEBSITES AS TOOLS OF PROMOTING HEALTH IN SOUTH EAST EUROPE Tasic, Lj
2002
5 6 p. 472-
1 p.
artikel
206 PIN32 A COMPARISON OF CONJOINT ANALYSIS AND TIME TRADE OFF ELICITED UTILITIES FOR QUALITY OF LIFE STATES ASSOCIATED WITH THE TREATMENT OF GENITAL HERPES Doward, LC
2002
5 6 p. 574-
1 p.
artikel
207 PIN37 A COMPREHENSIVE NATURAL HISTORY MODEL OF HUMAN PAPILLOMAVIRUS (HPV) INFECTION AND CERVICAL CANCER: POTENTIAL IMPACT OF AN HPV 16/18 VACCINE Goldie, S
2002
5 6 p. 576-
1 p.
artikel
208 PIN11 COMPARING HOSPITAL COSTS BETWEEN LINEZOLID AND VANCOMYCIN IN THE TREATMENT OF METHICILLIN-RESISTANT STAPHYLOCOCCAL SPECIES (MRSS) INFECTIONS:A RANDOMIZED MULTI-CENTER CLINICAL TRIAL Glick, HA
2002
5 6 p. 565-566
2 p.
artikel
209 PIN19 COST BENEFIT ANALYSIS ON VACCINATION FOR MEASLES IN JAPAN Takahashi, K
2002
5 6 p. 568-569
2 p.
artikel
210 PIN14 COST-CONSEQUENCE COMPARISON OF LOPINAVIR/RITONAVIR (LPV/r) VS. NELFINAVIR (NFV) THERAPY IN TREATING ANTIRETROVIRAL NAÏVE HIV PATIENTS USING CLINICAL TRIAL DATA Luo, MP
2002
5 6 p. 566-567
2 p.
artikel
211 PIN6 COST-EFFECTIVENESS ANALYSIS OF LINEZOLID VERSUS TEICOPLANIN IN THE TREATMENT OF INFECTIONS CAUSED BY GRAM-POSITIVE BACTERIA IN SPAIN Grau, S
2002
5 6 p. 563-
1 p.
artikel
212 PIN5 COST-EFFECTIVENESS OF DROTRECOGIN ALFA (ACTIVATED) FOR THE TREATMENT OF SEVERE SEPSIS:A CROSS-NATIONAL COMPARISON OF THREE EUROPEAN COUNTRIES Neilson, A
2002
5 6 p. 563-
1 p.
artikel
213 PIN4 COST-EFFECTIVENESS OF DROTRECOGIN ALFA (ACTIVATED) IN THE TREATMENT OF SEVERE SEPSIS IN SPAIN Sacristán, JA
2002
5 6 p. 562-
1 p.
artikel
214 PIN17 COST-EFFECTIVENESS OF 23-VALENT ANTIPNEUMOCOCCICAL VACCINATION IN CATALONIA (SPAIN) Plans-Rubió, P
2002
5 6 p. 568-
1 p.
artikel
215 PIN15 ECONOMIC BURDEN OF CHRONIC HEPATITIS B VIRUS INFECTION AND POTENTIAL COST SAVINGS WITH LAMIVUDINE Chen, X
2002
5 6 p. 567-
1 p.
artikel
216 PIN10 ECONOMIC EVALUATION DEMONSTRATES THAT MOXIFLOXACIN IV/PO MONOTHERAPY IS COST-EFFECTIVE TO THE SPANISH NATIONAL HEALTHCARE SYSTEM WHEN COMPARED TO IV/PO AMOXICILLIN/CLAVULANATE ± CLARITHROMYCIN IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA Drummond, M
2002
5 6 p. 565-
1 p.
artikel
217 PIN33 FACTORS INFLUENCING INAPPROPRIATE ANTIBIOTIC PRESCRIBING FOR CHILDREN WITH ACUTE BRONCHITIS IN AMBULATORY CARE SETTING Koompalum, D
2002
5 6 p. 574-575
2 p.
artikel
218 PIN13 FIVE-YEAR BUDGET IMPACT AND LIFETIME COST EFFECTIVENESS OF A LOPINAVIR/RITONAVIR (LVP/r) VS.A NELFINAVIR (NFV) CONTAINING REGIMEN FOR TREATMENT-NAÏVE PATIENTS Simpson, KN
2002
5 6 p. 566-
1 p.
artikel
219 PIN30 FURTHER DEVELOPMENT OF THE INFLUENZA DAILY DISRUPTION QUESTIONNAIRE Doll, HA
2002
5 6 p. 573-
1 p.
artikel
220 PIN21 HOSPITALISATION COSTS FOR YOUNG CHILDREN WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION Vergouwe, Y
2002
5 6 p. 569-570
2 p.
artikel
221 PIN24 IMPACT OF INFLUENZA VACCINATION ON WORK PRODUCTIVITY IN A COLOMBIAN COMPANY: COSTS AND BENEFITS FOR THE EMPLOYER Tasset, A
2002
5 6 p. 570-571
2 p.
artikel
222 PIN27 IMPACT OF SIMPLER HIV-THERAPY ON ADHERENCE AND QUALITY OF LIFE Arpinelli, F
2002
5 6 p. 572-
1 p.
artikel
223 PIN36 INCIDENCE OF SEVERE SEPSIS IN THE NETHERLANDS:A POINT PREVALENCE SURVEY Van Gestel, A
2002
5 6 p. 576-
1 p.
artikel
224 PIN16 INFLUENZA TREATMENT WITH OSELTAMIVIR IN A HIGH RISK POPULATION—A COSTEFFECTIVE OPTION FOR THE HEALTH CARE PAYER Sander, B
2002
5 6 p. 567-568
2 p.
artikel
225 PIN34 INITIAL ANTIVIRAL TREATMENT OF CHRONIC HEPATITIS C:A GERMAN HEALTH TECHNOLOGY ASSESSMENT AND DECISION ANALYSIS Siebert, U
2002
5 6 p. 575-
1 p.
artikel
226 PIN31 INVESTIGATION INTO THE FEASIBILITY OF DERIVING RELATIVE AND ABSOLUTE UTILITY FROM THE RECURRENT GENITAL HERPES QUALITY OF LIFE QUESTIONNAIRE (RGHQOL) Doward, LC
2002
5 6 p. 573-574
2 p.
artikel
227 PIN8 LENGTH OF STAY AND ANTIFUNGAL TREATMENTS COSTS IN PATIENTS WITH SYSTEMIC MYCOSIS: DESCRIPTION AND ASSOCIATED FACTORS Peiró, S
2002
5 6 p. 564-
1 p.
artikel
228 PIN7 OUTCOMES AND PATIENT CHARACTERISTICS ASSOCIATED WITH SYSTEMIC FUNGAL INFECTIONS Santiago, JY
2002
5 6 p. 563-564
2 p.
artikel
229 PIN12 PHARMACOECONOMIC ANALYSIS OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS TREATMENT WITH TELITHROMYCIN OR CEFUROXIME-AXETIL Rubio-Terrés, C
2002
5 6 p. 566-
1 p.
artikel
230 PIN9 PHARMACOECONOMIC ANALYSIS OF COMMUNITY ACQUIRED PNEUMONIA TREATMENT WITH TELITHROMYCIN OR CLARITHROMYCIN Rubio-Terrés, C
2002
5 6 p. 564-565
2 p.
artikel
231 PIN23 PHARMACOECONOMIC EVALUATION OF ANTIBACTERIALS UTILIZATION IN PRIMARY, SECONDARY AND TERTIARY HOSPITALS IN DEVELOPING ECONOMY Suleiman, IA
2002
5 6 p. 570-
1 p.
artikel
232 PIN22 PHARMACOECONOMIC EVALUATION OF STREPTOMYCIN VERSUS ETHAMBUTOL AS PRIMARY ANTITUBERCULAR DRUGS IN LAGOS UNIVERSITY TEACHING HOSPITAL Suleiman, IA
2002
5 6 p. 570-
1 p.
artikel
233 PIN29 PSYCHOMETRIC PROPERTIES OF THE MODIFIED VIH-47 IN A THERAPEUTIC TRIAL EVALUATING THE IMPACT OF AN EDUCATIONAL PROGRAM IN HIV + PATIENTS Arnould, B
2002
5 6 p. 573-
1 p.
artikel
234 PIN18 RELEVANCE OF COMPLICATIONS AS COST DRIVERS OF VARICELLA Klose, T
2002
5 6 p. 568-
1 p.
artikel
235 PIN28 REVIEW OF QOL AND HRQOL INSTRUMENTS AVAILABLE FOR MEASURING OUTCOME IN HIV/AIDS Meads, DM
2002
5 6 p. 572-
1 p.
artikel
236 PIN2 SEVERE SEPSIS: CLINICAL TRIAL VERSUS DAILY PRACTICE.A COST ANALYSIS IN BELGIUM Laterre, PF
2002
5 6 p. 561-562
2 p.
artikel
237 PIN20 THE COST-EFFECTIVENESS OF ANTIRETROVIRAL REGIMENS CONTAINING PROTEASE INHIBITORS (PIS) OR NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTI) IN THE TREATMENT OF HIV-INFACTED INDIVIDUALS IN POLAND Kowalik, E
2002
5 6 p. 569-
1 p.
artikel
238 PIN26 THE COST EFFECTIVENESS OF SAFE AND APPROPRIATE USE OF INJECTION POLICIES IN HEALTH CARE SETTINGS Dziekan, G
2002
5 6 p. 571-572
2 p.
artikel
239 PIN1 THE COSTS OF SEVERE SEPSIS—THE NETHERLANDS, 2000 Van Gestel, A
2002
5 6 p. 558-
1 p.
artikel
240 PIN3 THE TREATMENT OF SEPSIS PATIENTS WITH DROTRECOGIN ALFA (ACTIVATED):AN ECONOMIC EVALUATION WITH REFERENCE TO ITALY Lucioni, C
2002
5 6 p. 562-
1 p.
artikel
241 PIN25 VACCINATION IN HEALTHY WORKING ADULTS:WHAT RETURN ON INVESTMENT FOR COMPANIES? AN INTERNATIONAL PERSPECTIVE Anne, T
2002
5 6 p. 571-
1 p.
artikel
242 PIN35 VARICELLA VACCINATION OF PRE-SCHOOL CHILDREN: DETERMINING OPTIMAL COVERAGE LEVELS Klose, T
2002
5 6 p. 575-576
2 p.
artikel
243 PMD19 A CRITICAL REVIEW OF HEALTH-RELATED PRODUCTIVITY MEASURES Prasad, M
2002
5 6 p. 535-536
2 p.
artikel
244 PMD11 A DALY IS A QALY—OR IS IT? Essink-Bot, ML
2002
5 6 p. 532-533
2 p.
artikel
245 PMD16 ASSESSING QUALITY OF LIFE IN THE ELDERLY: A COMPARISON OF TWO UTILITY MEASURES Holland, R
2002
5 6 p. 534-
1 p.
artikel
246 PMD17 ASSESSMENT OF QUALITY OF LIFE IN CHILDREN: METHOLOGICAL AND CONCEPTUAL ISSUES Matza, LS
2002
5 6 p. 535-
1 p.
artikel
247 PMD9 BEHAVIOURAL ECONOMICS:THE IMPORTANCE OF ABSOLUTE AND RELATIVE HEALTH OUTCOMES Van Exel, J
2002
5 6 p. 532-
1 p.
artikel
248 PMD12 GENERIC VERSUS TREATMENT SPECIFIC TREATMENT SATISFACTION MEASUREMENT Brod, M
2002
5 6 p. 533-
1 p.
artikel
249 PMD10 ISPOR QUALITY OF LIFE SPECIAL INTEREST GROUP TRANSLATION AND CULTURAL ADAPTATION: PROGRESS ON THE DEVELOPMENT OF PRINCIPLES OF BEST PRACTICE Wild, DJ
2002
5 6 p. 532-
1 p.
artikel
250 PMD6 MODIFYING COST-EFFECTIVENESS RATIOS TO BE MAXIMALLY COMPARABLE ACROSS MULTIPLE DISEASES:AN APPLICATION OF MANIFOLD THEORY Gold, K
2002
5 6 p. 530-531
2 p.
artikel
251 PMD3 RELEVANCE OF PATIENT REPORTED OUTCOMES FOR CHRONIC PAIN PATIENTS: THE ROLE OF SATISFACTION WITH ANALGESIC MEDICATION AND APPLICATION FORM Anderson-Hillemacher, A
2002
5 6 p. 529-530
2 p.
artikel
252 PMD14 THE INFLUENCE OF ILLNESS EXPERIENCE ON HEALTH STATE VALUATIONS Joore, MA
2002
5 6 p. 533-534
2 p.
artikel
253 PMD15 THE INFLUENCE OF ILLNESS EXPERIENCE ON VALUATION COMPRESSION Joore, MA
2002
5 6 p. 534-
1 p.
artikel
254 PMD18 THE INTERNATIONAL HEALTH-RELATED QUALITY OF LIFE OUTCOMES DATABASE (IQOD) PROGRAMME—WHQ AND PGWBI DATABASES: REFERENCES VALUES FOR CROSSCULTURAL COMPARISONS Lobo-Luppi, L
2002
5 6 p. 535-
1 p.
artikel
255 PMD1 THE NEW METHOD FOR TIME ADJUSTMENT OF THE NUMBER NEEDED TO TREAT AND ITS APPLICATION TO PHARMACOECONOMICS ANALYSIS Aino, H
2002
5 6 p. 529-
1 p.
artikel
256 PMD13 THE RELEVANCE OF QUANTITY AND QUALITY OF LIFE-YEARS AFTER TREATMENT IN PRIORITIZING BETWEEN DIFFERENT PATIENTS Arnold, SV
2002
5 6 p. 533-
1 p.
artikel
257 PMD2 THE USE OF DISCRETE CHOICE MODELLING IN THE DESIGN OF CLINICAL TRIALS Backhouse, ME
2002
5 6 p. 529-
1 p.
artikel
258 PMD8 TRENDS IN DATA SOURCES USED FOR ECONOMIC EVALUATION Boler, A
2002
5 6 p. 531-532
2 p.
artikel
259 PMD7 VALUATION OF INFORMAL CARE:THE OPPORTUNITY COST METHOD APPLIED IN CAREGIVING FOR STROKE AND RHEUMATOID ARTHRITIS PATIENTS Van den Berg, B
2002
5 6 p. 531-
1 p.
artikel
260 PMD5 VALUATION OF NEW DRUG APPLICATIONS OF PHARMACEUTICAL COMPANIES USING COMPOUND OPTION MODELS Cassimon, D
2002
5 6 p. 530-
1 p.
artikel
261 PMD4 WHEN CAN MISSING DATA BE CONSIDERED MISSING AT RANDOM (MAR) IN SUBSTANCE ABUSE TREATMENT OUTCOMES RESEARCH? Ciesla, JR
2002
5 6 p. 530-
1 p.
artikel
262 PMH3 A COST-EFFECTIVENESS COMPARISON OF OLANZAPINE AND RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA IN ITALY Beard, S
2002
5 6 p. 515-
1 p.
artikel
263 PMH22 ADHD HAS A SIGNIFICANT BURDEN UPON THE INDIVIDUAL, FAMILY AND SOCIETY IN EUROPE Ralston, SJ
2002
5 6 p. 522-523
2 p.
artikel
264 PMH5 A DISCRETE EVENTS MODEL OF LONG-TERM OUTCOMES AND COST OF TREATMENT WITH LONG ACTING RISPERIDONE IN SCHIZOPHRENIA Heeg, BM
2002
5 6 p. 515-516
2 p.
artikel
265 PMH11 ANTIPSYCHOTIC MEDICATION PATTERNS IN SCHIZOPHRENIA OUTPATIENTS AND INPATIENTS TREATED WITH OLANZAPINE AND HALOPERIDOL IN GERMANY: RESULTS FROM THE GEO OBSERVATIONAL STUDY Eichmann, F
2002
5 6 p. 518-
1 p.
artikel
266 PMH2 ANTIPSYCHOTIC USE PATTERNS AND HEALTHCARE COSTS FOR INDIVIDUALS WITH SCHIZOPHRENIA TREATED WITH HALOPERIDOL, OLANZAPINE OR RISPERIDONE IN A MEDICAID POPULATION Ramsey, JL
2002
5 6 p. 514-
1 p.
artikel
267 PMH23 ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD):A RECOGNISED DISORDER FOR CHILDREN IN EUROPE Ralston, SR
2002
5 6 p. 523-
1 p.
artikel
268 PMH7 BOTTOM-UP OR TOP-DOWN? IMPACT OF PATIENT SELECTION ON COST-OF-ILLNESS RESULTS van Asselt, ADI
2002
5 6 p. 516-
1 p.
artikel
269 PMH25 CORRESPONDENCE COURSE FOR GPS IMPROVED QUALITY AND PERSISTENCY OF ANTI-DEPRESSIVE THERAPY (RESULTS FROM THE IMPROVE-D STUDY) Michalek, HE
2002
5 6 p. 524-
1 p.
artikel
270 PMH8 COST-EFFECTIVENESS OF MIRTAZAPINE COMPARED TO FLUOXETINE IN THE TREATMENT OF MODERATE AND SEVERE DEPRESSION IN HUNGARY Van Loon, J
2002
5 6 p. 517-
1 p.
artikel
271 PMH6 DIRECT MEDICAL COSTS FOR TREATMENT OF PATIENTS EXPERIENCING BIPOLAR DISORDER EPISODES IN THE UK Finnern, HW
2002
5 6 p. 516-
1 p.
artikel
272 PMH9 ESTIMATING COST-EFFECTIVENESS OF CONCERTA OROS IN ATTENTIONDEFICIT/HYPERACTIVITY DISORDER (ADHD)—ADAPTING THE CANADIAN COORDINATING OFFICE FOR HEALTH TECHNOLOGY ASSESSMENT'S (CCOHTA) ECONOMIC MODEL OF METHYLPHENIDATE IMMEDIATE RELEASE VERSUS BEHAVIOURAL INTERVENTIONS FROM A PARENT'S PERSPECTIVE Annemans, L
2002
5 6 p. 517-
1 p.
artikel
273 PMH4 ESTIMATING MEDICAL COST REDUCTION IN TREATING SCHIZOPHRENIA WITH CLOZAPINE Sendersky, V
2002
5 6 p. 515-
1 p.
artikel
274 PMH18 EVALUATION OF CLINICAL EFFICACY OF WEEKLY FLUOXETIN COMPARED WITH DAILY FLUOXETIN 40 MG IN AMBULATORY PATIENTS WITH MAJOR DEPRESSION Ortega, T
2002
5 6 p. 521-
1 p.
artikel
275 PMH19 GENDER DIFFERENCES IN PSYCHOACTIVE MEDICATION TREATMENT FOR ATTENTIONDEFICIT/HYPERACTIVITY DISORDER (AD/HD): RESULTS FROM A POPULATION-BASED STUDY Barbaresi, WJ
2002
5 6 p. 521-522
2 p.
artikel
276 PMH21 IMPROVING THE MEASUREMENT PROPERTIES OF THE QUALITY OF LIFE IN DEPRESSION SCALE McKenna, SP
2002
5 6 p. 522-
1 p.
artikel
277 PMH14 INCIDENCE OF HYPERLIPIDEMIA DURING TREATMENT OF SCHIZOPHRENIA: FINDINGS IN A CLAIMS DATABASE Zhao, Z
2002
5 6 p. 519-520
2 p.
artikel
278 PMH10 LENGTH OF STAY AND ANTIPSYCHOTIC TREATMENT COSTS OF PATIENTS WITH ACUTE PSYCHOSIS ADMITTED TO HOSPITAL: DESCRIPTION AND ASSOCIATED FACTORS— THE PSYCHOSP STUDY Peiró, S
2002
5 6 p. 518-
1 p.
artikel
279 PMH12 PATIENT AND DISEASE CHARACTERISTICS IN SCHIZOPHRENIA OUTPATIENTS AND INPATIENTS TREATED WITH OLANZAPINE AND HALOPERIDOL IN GERMANY: RESULTS FROM THE GEO OBSERVATIONAL STUDY Eichmann, F
2002
5 6 p. 518-519
2 p.
artikel
280 PMH16 RECRUITMENT FOR SCHIZOPHRENIA RESEARCH: EXPLORING THE DIFFERENCES BETWEEN COMMUNITY MENTAL HEALTH CENTERS AND NATIONAL ALLIANCE FOR THE MENTALLY ILL Mackell, J
2002
5 6 p. 520-
1 p.
artikel
281 PMH15 SEXUAL DYSFUNCTION AND ANTIPSYCHOTIC DRUG ADHERENCE IN PEOPLE WITH SCHIZOPHRENIA Weiden, PJ
2002
5 6 p. 520-
1 p.
artikel
282 PMH26 SIMULATING THE COURSE OF SCHIZOPHRENIA USING DISCRETE EVENTS MODELLING Heeg, BM
2002
5 6 p. 524-
1 p.
artikel
283 PMH13 STUDY DESCRIPTION AND BASELINE RESULTS OF THE SCHIZOPHRENIA OUTCOMES SURVEY (SOS) OBSERVATIONAL STUDY IN BELGIUM Annemans, L
2002
5 6 p. 519-
1 p.
artikel
284 PMH20 THE EFFECTS OF ETHNICITY AND ANTIPSYCHOTIC AGENT ON MEDICATION ADHERENCE IN A MEDICAID POPULATION Opolka, J
2002
5 6 p. 522-
1 p.
artikel
285 PMH1 THE HEALTH CARE COSTS OF SCHIZOPHRENIA IN AUSTRALIA: 18-MONTH FOLLOW-UP RESULTS Christova, L
2002
5 6 p. 514-
1 p.
artikel
286 PMH24 THERE ARE SIGNIFICANT BARRIERS TO THE DIAGNOSIS AND TREATMENT OF ADHD IN EUROPE Ralston, SJ
2002
5 6 p. 523-524
2 p.
artikel
287 PMH17 TREATMENT SATISFACTION AND COMPLIANCE WITH RISPERIDONE USE IN PATIENTS WITH BIPOLAR DISORDER Bolge, SC
2002
5 6 p. 520-521
2 p.
artikel
288 PNP8 ADJUNCTIVE TOPIRAMATE THERAPY IN PATIENTS WITH REFRACTORY SEIZURES:A LIFETIME COST-UTILITY ANALYSIS Maltoni, S
2002
5 6 p. 509-510
2 p.
artikel
289 PNP1 CHOLINESTERASE INHIBITORS REDUCE INSTITUTIONALIZATION RISK AND MAY REDUCE OVERALL ECONOMIC BURDEN FOR PATIENTS WITH DEMENTIA IN A NATURALISTIC TREATMENT SETTING Luong, D
2002
5 6 p. 507-
1 p.
artikel
290 PNP17 COMPLIANCE OF TWO TREATMENTS OF ALZHEIMER'S DISEASE Barbeau, M
2002
5 6 p. 513-
1 p.
artikel
291 PNP5 DIRECT COSTS OF BACK PAIN IN THE UNITED STATES:A NATIONAL ESTIMATE Mychaskiw, MA
2002
5 6 p. 508-509
2 p.
artikel
292 PNP7 ECONOMIC EVALUATION OF LEVETIRACETAM AS ADJUNCTIVE THERAPY IN REFRACTORY EPILEPTIC PATIENTS Blais, L
2002
5 6 p. 509-
1 p.
artikel
293 PNP10 ECONOMIC IMPACT OF GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS Ollendorf, DA
2002
5 6 p. 510-511
2 p.
artikel
294 PNP2 ECONOMIC IMPACT OF TREATMENT OF DEMENTIA FOR GERMANY—A PROGNOSIS TO 2050 Happich, MV
2002
5 6 p. 507-
1 p.
artikel
295 PNP15 EVALUATION OF THE RELATIONSHIP BETWEEN EPILEPSY SEVERITY AND UTILITY Selai, C
2002
5 6 p. 512-513
2 p.
artikel
296 PNP18 FORMULARY DECISION SUPPORT FOR INTERFERON-BETA-1A USING ANALYSIS OF CARE-SEEKING BEHAVIOR FOR MULTIPLE SCLEROSIS Meyer, C
2002
5 6 p. 513-514
2 p.
artikel
297 PNP16 MEDICATION USE IN PATIENTS WITH LOW BACK PAIN: DATA FROM MANAGED CARE Harley, C
2002
5 6 p. 513-
1 p.
artikel
298 PNP12 PHYSICIAN PREFERENCE FOR ANTIEPILEPTIC DRUG CONCENTRATION TESTING Baumann, RJ
2002
5 6 p. 511-
1 p.
artikel
299 PNP13 QUALITY OF LIFE (QOL) AND PHARMACOECONOMICAL ASPECTS IN PATIENTS WITH SYMPTOMATIC LOCALIZATION-RELATED EPILEPSIES (SLE) IN MOSCOW Guekht, AB
2002
5 6 p. 511-512
2 p.
artikel
300 PNP9 RETROSPECTIVE EVALUATION OF DYSPORTTM AND BOTOXTM DRUG UTILIZATION IN THE MANAGEMENT OF PATIENTS WITH CERVICAL DYSTONIA OR BLEPHAROSPASM Magar, R
2002
5 6 p. 510-
1 p.
artikel
301 PNP3 SOCIO-ECONOMIC IMPACT OF CHRONIC DAILY HEADACHE IN THE GENERAL POPULATION IN FRANCE Lantéri-Minet, M
2002
5 6 p. 507-508
2 p.
artikel
302 PNP4 SWITCHING AND PERSISTENCY IN A NSAID AND COX-2 SPECIFIC INHIBITOR USER POPULATION IN MANAGED CARE Harley, C
2002
5 6 p. 508-
1 p.
artikel
303 PNP6 THE BURDEN OF MIGRAINE: BEYOND DIRECT HEALTH CARE COSTS Badia, X
2002
5 6 p. 509-
1 p.
artikel
304 PNP11 USE OF THE TOPS AS A PAIN-SPECIFIC HRQOL INSTRUMENT Oderda, GM
2002
5 6 p. 511-
1 p.
artikel
305 POD1 AN ECONOMIC EVALUATION OF NOVOSEVEN IN THE MANAGEMENT OF HAEMOPHILIA PATIENTS WITH INHIBITORS IN SLOVAKIA Hart, WM
2002
5 6 p. 576-577
2 p.
artikel
306 POD9 A PHARMACOECONOMIC EVALUATION OF THE USE OF THYROTROPIN-ALFA (THYROGEN®) IN THE DETECTION OF THYROID REMNANTS AND WELLDIFFERENTIATED THYROID CANCER IN THE DUTCH HEALTH CARE SETTING de Peuter, MA
2002
5 6 p. 580-
1 p.
artikel
307 POD2 DEVELOPMENT OF ECONOMIC AND OUTCOMES MODEL OF HEMOPHILIA TREATMENT IN LATIN AMERICA AND SOUTH Roberts, H
2002
5 6 p. 577-
1 p.
artikel
308 POD6 ELECTRONIC IMPLEMENTION OF AN APPROVED TABLET SPLITTING GUIDE WITH PROVIDER ORDER ENTRY—ASSOCIATED COST SAVINGS Schaefer, MG
2002
5 6 p. 578-579
2 p.
artikel
309 POD5 EVALUATION OF A PALLIATIVE CARE TEAM ON RESOURCE UTILIZATION IN AN ACUTE CARE SETTING Conner, T
2002
5 6 p. 578-
1 p.
artikel
310 POD10 IMPROVEMENT IN QUALITY OF LIFE IN GROWTH HORMONE (GH) REPLACED HYPOPITUITARY ADULTS WITH GH DEFICIENCY IS CORRELATED WITH PATIENTREPORTED OUTCOMES:ANALYSIS OF THE KIMS DATABASE Koltowska-Häggström, M
2002
5 6 p. 580-
1 p.
artikel
311 POD4 INCIDENCE AND PREVENTION OF NEEDLE STICK INJURY RELATED TO SUBCUTANEOUS INJECTION: EXAMPLE OF THE IMPACT OF A LOW MOLECULAR WEIGHT HEPARIN SAFETY SYRINGE Bouvet, E
2002
5 6 p. 578-
1 p.
artikel
312 POD3 JOINT RECOVERY IN HIP AND KNEE REPLACEMENT:A COST-EFFECTIVE APPROACH Brunenberg, D
2002
5 6 p. 577-
1 p.
artikel
313 POD8 THE COST-EFFECTIVENESS OF OSTEOGENIC PROTEIN 1 IN THE TREATMENT OF TIBIAL NONUNIONS IN THE UK AND GERMANY van Engen, AK
2002
5 6 p. 579-
1 p.
artikel
314 POD7 THE IMPACT OF FALLING ON HEALTH CARE UTILIZATION AND COSTS:A COMPARISON OF PROPENSITY SCORING AND TWO-PART MODELS Rizzo, JA
2002
5 6 p. 579-
1 p.
artikel
315 PRK4 AN ECONOMIC MODEL OF UNSTABLE BLADDER IN BELGIUM Kurth, H
2002
5 6 p. 582-
1 p.
artikel
316 PRK12 APPLYING CONJOINT ANALYSIS TO THE VALUATION OF OVERACTIVE BLADDER DRUGEFFICACY VARIABLES AND SIDE EFFECTS Brown, MCJ
2002
5 6 p. 585-
1 p.
artikel
317 PRK1 ASSESSING PROVIDER TIME FOR ANAEMIA MANAGEMENT OF DIALYSIS PATIENTS USING TIME & MOTION METHODS:A MULTI-CENTRE OBSERVATIONAL STUDY IN EUROPE De Cock, E
2002
5 6 p. 581-
1 p.
artikel
318 PRK5 A STRAIGHTFORWARD COST-EFFECTIVENESS ANALYSIS OF LONG-ACTING TREATMENTS FOR OVERACTIVE BLADDER: CAN IT BE THIS SIMPLE? Noe, LL
2002
5 6 p. 582-583
2 p.
artikel
319 PRK15 A SURVEY ON THE CLINICAL MANAGEMENT OF CMV RISK IN PATIENTS FOLLOWING RENAL TRANSPANTATION IN FRANCE Legendre, C
2002
5 6 p. 586-
1 p.
artikel
320 PRK11 BPH AND IPSS SCORES EVALUATED AFTER SIX MONTHS ACCORDING TO THE TYPE OF DISEASE MANAGEMENT Taöeb, C
2002
5 6 p. 584-585
2 p.
artikel
321 PRK3 BRANDED VS GENERIC CYCLOSPORINE IN DE-NOVO KIDNEY TRANSPLANTATION—WHERE ARE THE COST SAVINGS? Pirk, O
2002
5 6 p. 581-582
2 p.
artikel
322 PRK2 COSTS OF CHRONIC KIDNEY DISEASE (CKD): COST AND COMORBIDITY Smith, DH
2002
5 6 p. 581-
1 p.
artikel
323 PRK6 EVALUATING THE COST OF LONG-ACTING TREATMENTS FOR OVERACTIVE BLADDER Becker, RV
2002
5 6 p. 583-
1 p.
artikel
324 PRK8 HEALTH RELATED QUALITY OF LIFE (HRQOL) IN CHRONIC DIALYSIS PATIENTS:A CRITICAL COMPARISON OF CONTINUOUS AMBULATORY PERITONEAL DIALYSIS (CAPD) AND CENTRE HEMODIALYSIS (CHD) Procaccini, DA
2002
5 6 p. 583-584
2 p.
artikel
325 PRK7 PATIENTS ARE SATISFIED WITH TELEMEDICINE (HOME-CARE) Marchetti, M
2002
5 6 p. 583-
1 p.
artikel
326 PRK9 PATIENTS TREATED WITH SERENOA REPENS: EVOLUTION OF THE IPSS SCORES IN TERMS OF IRRITATION AND OBSTRUCTION Taöeb, C
2002
5 6 p. 584-
1 p.
artikel
327 PRK10 PATIENTS TREATED WITH SERENOA REPENS: EVOLUTION OF THE SCORES SPI AND SF12 Taöeb, C
2002
5 6 p. 584-
1 p.
artikel
328 PRK14 PREVALENCE OF APPROPRIATE URINARY INCONTINENCE EVALUATIONS IN TEXAS NURSING HOME FACILITIES Monroe, DM
2002
5 6 p. 585-586
2 p.
artikel
329 PRK13 REGIONAL SIMILARITIES IN IMPROVEMENT AND PERSISTENCE OF SHORT-TERM HEALTH-RELATED QUALITY OF LIFE EFFECT OF TOLTERODINE ON OVERACTIVE BLADDER PATIENTS Pleil, AM
2002
5 6 p. 585-
1 p.
artikel
330 PRP10 A DISEASE MANAGEMENT PROGRAM IN FRANCE: LESSONS FROM THE RESALIS EXPERIMENT 18 MONTHS BEFORE AND 12 MONTHS AFTER PUBLIC HEALTH INTERVENTIONS Launois, R
2002
5 6 p. 528-
1 p.
artikel
331 PRP3 AN ANALYSIS OF THE LENGTH AND COSTS OF RESPIRATOR USE WITH OBSERVATIONAL DATA BASED ON MEDICAL RECORDS Watanabe, R
2002
5 6 p. 525-
1 p.
artikel
332 PRP6 ASSESSMENT OF RESPIRATORY DISEASE SEVERITY USING POSTAL QUESTIONNAIRES Hazell, ML
2002
5 6 p. 526-527
2 p.
artikel
333 PRP5 EPIDEMIOLOGICAL STUDY ESTIMATING THE PREVALENCE OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS IN GERMANY Elies, W
2002
5 6 p. 526-
1 p.
artikel
334 PRP9 EVALUATION OF A DISEASE MANAGEMENT PROGRAM (DMP) FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN GERMANY: PRELIMINARY ASSESSMENT OF EFFECTIVENESS OF COMPOUNDS Lorenz, J
2002
5 6 p. 528-
1 p.
artikel
335 PRP7 HEALTH RELATED QUALITY OF LIFE (HRQOL) IN ASTHMA PATIENTS IN RELATIONSHIP TO ASTHMA SEVERITY DEGREE Rebollo, P
2002
5 6 p. 527-
1 p.
artikel
336 PRP4 INHALED ANTIINFLAMMATORY MEDICATION USE AND SUBSEQUENT HOSPITALIZATIONS AMONG TEXAS MEDICAID PATIENTS WITH PERSISTENT ASTHMA Smith, M
2002
5 6 p. 526-
1 p.
artikel
337 PRP1 INPATIENT AND OBSERVATION UNIT COSTS FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) O'Brien, JA
2002
5 6 p. 525-
1 p.
artikel
338 PRP8 QUALITY OF LIFE AND COSTS FOR MODERATE AND SEVERE ASTHMA IN FRANCE Lafuma, A
2002
5 6 p. 527-
1 p.
artikel
339 PRP2 3329 STUDY TO EVALUATE HOSPITAL COSTS FOR ACUTE EXACERBATION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN SPAIN (EPOC-COST STUDY) García, A
2002
5 6 p. 525-
1 p.
artikel
340 PWM9 ASSOCIATION BETWEEN PATERNAL EXPOSURE TO SOLVENTS AND FETAL MALFORMATIONS de vries, LE
2002
5 6 p. 590-
1 p.
artikel
341 PWM8 ASSOCIATION BETWEEN PATERNAL EXPOSURE TO SOLVENTS AND SPONTANEOUS ABORTIONS Logman, JFS
2002
5 6 p. 589-
1 p.
artikel
342 PWM2 COST ANALYSIS OF IVF TREATMENT WITH INJECTION DEVICE VS THE TRADITIONAL SYRINGE AND NEEDLE Johannes, E
2002
5 6 p. 587-
1 p.
artikel
343 PWM1 HEALTH CARE RESOURCE USE FOR HEAVY MENSTRUAL LOSS Jacobs, P
2002
5 6 p. 586-587
2 p.
artikel
344 PWM4 INFLUENCE OF ERECTILE DYSFUNCTION ON HEALTH RELATED QUALITY OF LIFE OF MALE KIDNEY TRANSPLANT PATIENTS ACCORDING TO AGE Rebollo, P
2002
5 6 p. 587-588
2 p.
artikel
345 PWM6 POST-MENOPAUSAL HORMONE THERAPY: DO HYPERTENSION AND THROMBOPHILIA MATTER? Marchetti, M
2002
5 6 p. 588-589
2 p.
artikel
346 PWM5 PRELIMINARY VALIDATION OF A NEW DISEASE-SPECIFIC UTILITY MEASURE FOR ERECTILE DYSFUNCTION Torrance, G
2002
5 6 p. 588-
1 p.
artikel
347 PWM3 SECOND-GENERATION VERSUS FIRSTGENERATION ENDOMETRIAL ABLATION TECHNIQUES IN THE TREATMENT OF DYSFUNCTIONAL UTERINE BLEEDING (DUB):A REVIEW OF THE LITERATURE Lessard, C
2002
5 6 p. 587-
1 p.
artikel
348 PWM7 USING A DISCRETE CHOICE EXPERIMENT TO VALUE AN INJECTION DEVICE FOR INFERTILITY TREATMENT Brown, RE
2002
5 6 p. 589-
1 p.
artikel
349 PWM10 VITAMIN USE AMONG WOMEN OF CHILDBEARING AGE IN US: EVIDENCE FROM THE 1997 MEPS DATA DeVeaugh-Geiss, A
2002
5 6 p. 590-
1 p.
artikel
350 Subject Index, Volume 5 2002
5 6 p. 607-609
3 p.
artikel
351 UT5 COMPARISON OF THE SF6D AND THE EQ5D IN PATIENTS REQUIRING CORONARY REVASCULARISATION van Stel, HF
2002
5 6 p. 461-
1 p.
artikel
352 UT3 ESTIMATING HEALTH UTILITY FROM A PHYSICAL FUNCTION ASSESSMENT IN RHEUMATOID ARTHRITIS (RA) PATIENTS TREATED WITH ADALIMUMAB (D2E7) Boggs, R
2002
5 6 p. 452-453
2 p.
artikel
353 UT6 IMPROVEMENT IN HEALTH UTILITY AMONG RHEUMATOID ARTHRITIS (RA) PATIENTS TREATED WITH ADALIMUMAB (D2E7), A FULLY HUMAN ANTI-TNF MONOCLONAL ANTIBODY van de Putte, L
2002
5 6 p. 461-
1 p.
artikel
354 UT1 36 INTO 1 DOESN'T GO Kind, P
2002
5 6 p. 452-
1 p.
artikel
355 UT4 PATIENT-DERIVED UTILITY ESTMATES OF CHRONIC HEPATITIS C BASED ON EQ-5D AND RS SCORES Greiner, W
2002
5 6 p. 460-461
2 p.
artikel
356 UT2 THE TRANSFORMATION OF SOCIAL PREFERENCE WEIGHTS: IMPLICATIONS FOR COST-EFFECTIVENESS Cleemput, I
2002
5 6 p. 452-
1 p.
artikel
357 WD1 NHP AND 15D PERFORM WELL IN ASSESSMENT OF THE HRQOL OF HEALTHY WOMEN WITH HORMONE REPLACEMENT THERAPY Sintonen, H
2002
5 6 p. 447-
1 p.
artikel
358 WD3 PATIENT PREFERENCE AND WILLINGNESS-TO-PAY IN FIVE EUROPEAN COUNTRIES FOR HUMALOG MIX25 COMPARED TO HUMULIN 30/70 FOR THE TREATMENT OF TYPE 2 DIABETES Aristides, M
2002
5 6 p. 448-
1 p.
artikel
359 WD2 PRE-TERM PREGNANCY TERMINATIONS FOLLOWING EXPOSURE TO ANTIDEPRESSANTS:A META-ANALYSIS Hemels, MEH
2002
5 6 p. 447-
1 p.
artikel
360 WP2 ESTIMATING WILLINGNESS TO PAY FOR DRUGS TO TREAT ADHD—A CONTINGENT VALUATION STUDY IN STUDENTS De Ridder, A
2002
5 6 p. 462-
1 p.
artikel
361 WP3 WILLINGNESS TO PAY FOR A PHARMACIST INTERVENTION PROGRAM AMONG NONCOMPLIANT DYSLIPIDEMIA PATIENTS Ali, F
2002
5 6 p. 462-463
2 p.
artikel
362 WP1 WILLINGNESS TO PAY FOR PHARMACISTPROVIDED MENOPAUSE AND HORMONE REPLACEMENT THERAPY CONSULTATIONS Branvold, AE
2002
5 6 p. 462-
1 p.
artikel
                             362 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland